medigraphic.com
Colegio de Medicina Interna de México.

2005, Number 6

<< Back Next >>

Med Int Mex 2005; 21 (6)

Pharmacological surveillance in hospitalized patients

Carranza MJ

Language: Spanish
References: 22
Page: 417-425
PDF size: 63.45 Kb.


ABSTRACT

Background: Although in Mexico City there is a National Pharmacological Surveillance System, which receives the adverse drug reactions reports from physicians and the pharmaceutical industry, there are not permanent pharmacological surveillance programs in hospitalized patients that allow us to know the frequency and severity of adverse drug events.
Objectives: To propose a pharmacological surveillance method in hospitalized patients and to know the frequency and severity of adverse drug reactions in an Internal Medicine Department.
Patients and methods: 81 patients hospitalized in an Internal Medicine Department were included in an open, prospective, and longitudinal trial. From their admission to the hospital discharge they were asked for: diagnosis, clinical, laboratory and radiological manifestations, treatments and adverse drug events.
Results: Adverse drug reactions were found in 29.6% of the inpatients, most of them in women (66.6%); 13.5% were classified as severe adverse drug reactions. 55.1% of them were due to the extended pharmacological drug effects. Mean hospitalization stay was 8.6 days and the mean number of prescribed drugs per patient was 5.8.
Conclusions: This trial suggests that the frequency of adverse drug reactions in our inpatients is high. This kind of pharmacological surveillance programs may be useful for the definition, review and updating of the basic scheme of drugs of the Mexican Health Secretariat.


REFERENCES

  1. Chyka PA. How many deaths occur annually from adverse drug reactions in the United States? Am J Med 2000;109(2):122-30.

  2. Organización Mundial de la Salud. Vigilancia farmacológica. Series de informes clínicos, 1972;núm.498.

  3. Morreli HF, Melmon KL. Drug reactions in clinical pharmacology. 2nd ed. London: MacMillan, 1978;pp:951-81.

  4. Registry of adverse drug reactions. Report of the Drug Reaction Registry Subcommittee of the Greater Philadelphia Committee for Medical-Pharmaceutical Sciences. JAMA 1968;203:31-34.

  5. Hoddinot BC, Gowdey CW, Coulter WK, Parker JM, et al. Drug reactions and errors in administration on a medical ward. Can Med Assoc J 1967;97:1001-6.

  6. Olgilvie RI, Ruedy J. Adverse drug reactions during hospitalization. Can Med Assoc J 1967;97:1450-7.

  7. Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969;1:531-6.

  8. Mijangos-Huesca FJ, Luján M, Castelli P, López y Martínez E, Campillo C. Farmacovigilancia en un hospital de tercer nivel. Estudio piloto en el Servicio de Psiquiatría. Memorias del XVII Congreso Nacional de Farmacología, San Luis Potosí, SLP, 1995;pp:47.

  9. Becerril MC, Mercedes JL, Lesley JW. Sistema Nacional de Farmacovigilancia en México. En: Farmacovigilancia, una responsabilidad compartida. Glaxo Group Research Limited. Churchill Livingstone. Alhambra Longman SA, 1992;pp:95-106.

  10. Louik C, Lacouture PG, Mitchell AA, Kauffman R, et al. A study of adverse reaction algorithms in a drug surveillance program. Clin Pharmacol Ther 1985;38:183-7.

  11. Simmons, et al. Adverse drug reactions during hospitalization (letter). Can Med Assoc J 1968;98:175.

  12. Sánchez de Puerta MD, Navarrete S, Balfour NW. Cómo comunicar las sospechas de reacciones adversas a los medicamentos (RAM). En: Farmacovigilancia, una responsabilidad compartida. Glaxo Group Research Limited. Churchill Livingstone. Alhambra Longman SA 1992;pp:83-90.

  13. World Health Organization. Safety of medicines. A guide to detect and report adverse drug reactions. Why health professionals need to take action. Ginebra, 2002.

  14. Morreli HF, Melmon KL. Drug interactions in clinical pharmacology. 2nd ed. London: MacMillan, 1978;pp:982-1007.

  15. Classen DC, Pestonik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.

  16. Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results from the Harvard Medical Practice Study II. N Engl J Med 1991;324:377-84.

  17. Bates DW, Spell N, Cullen DJ, et al. The cost of adverse drug events in hospitalized patients. JAMA 1997;277:307-11.

  18. Leape LL, Spell N, Cullen DJ, et al. Systems analysis of adverse drug events. JAMA 1995;274:35-43.

  19. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995;274:29-34.

  20. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003;348:1556-64.

  21. Martin. Adverse drug reactions. In: Hazards of medication. Lippincot 1971;pp:321-77.

  22. Hurwitz N. Predisposing factors in adverse reactions to drugs. Br Med J 1969;1:536-9.




2020     |     www.medigraphic.com